Keytruda pembrolizumab regulatory update

FDA accepted and granted Priority Review to an sBLA from Merck for Keytruda pembrolizumab as a single agent to treat recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in patients with disease progression on or after platinum-containing chemotherapy. The PDUFA date is Aug. 9. ...